Introduction
The myelodysplastic syndromes (MDS) are predominantly diseases of the elderly (median age at diagnosis, 70 years) and are among the most common hematologic malignancies, affecting 1 in 500 persons over 65 years of age. [1] [2] [3] Patients present with cytopenias involving one or more blood cell lineages, bone marrow morphologic findings indicative of mono-, di-or trilineage dysplasia, and a variable risk of transformation to acute leukemia. Currently, allogeneic stem cell transplantation offers the only curative therapy for MDS, 4 but is not a realistic option for most elderly patients.
Cases of MDS are thought to arise from the clonal acquisition of mutations in multipotent hematopoietic stem cells, but the precise molecular abnormalities remain poorly defined. Bone marrow cytogenetic studies are helpful in this regard, revealing clonal abnormalities in 30-50% of cases, most frequently deletions of chromosomes 5, 7 and 20 and/or trisomy 8. 5 Cases with del(5q) as the sole abnormality, the so-called 5q syndrome, have shown remarkable responses to lenalidomide, 6 and haploinsufficiency for the ribosomal protein 14 (RPS14) gene appears to account for many of the clinical features of this syndrome. 7 This suggests that improved detection of clonal genomic aberrations in MDS could identify additional patients likely to respond well to lenalidomide or perhaps to DNA methyltransferase inhibitors, such as 5-azacitidine and decitabine. 8, 9 However, this leaves an estimated 50-70% of cases with normal bone marrow cell karyotypes for whom there are no molecular tests that could be used to distinguish between MDS and benign bone marrow cell diseases.
Recent studies of human cancers have indicated that small regions of specific clonal genomic abnormalities can be detected with high-density single nucleotide polymorphism (SNP) arrays, which provide a detailed structural examination of the cancer genome, including high-resolution analysis for loss of heterozygosity (LOH). 10 Two groups have applied this technology to the study of archival bone marrow samples from MDS patients, reporting a high frequency of detection of uniparental disomy (UPD) and copy number alterations, even in cases with a normal karyotype. [11] [12] [13] [14] [15] We were troubled by these reports, because the MDS bone marrow samples were analyzed without a paired buccal or other normal sample from the same patient. Instead, results were compared with those obtained from the blood cells of unrelated normal individuals. Without a paired analysis of bone marrow DNA with normal control DNA for each patient, we suspected that inherited copy number variations (CNVs) and genomic regions with apparent homozygosity due to linkage disequilibrium or consanguinity might confound the detection of somatically acquired abnormalities linked to the pathogenesis of the malignant clone. Thus, we undertook a prospective study of adults with MDS in which SNP array findings from bone marrow cell DNA were compared with those from matched control normal DNA extracted from autologous buccal swabs. We identified unambiguous, somatically acquired abnormalities with this approach in patients whose bone marrow cells had a normal karyotype, although at a lower frequency than has been previously reported.
11-15 Importantly, we found that paired analysis of bone marrow and normal (buccal) DNA from each patient was necessary to distinguish acquired clonal abnormalities from inherited genomic variations.
Materials and methods

Patients and clinical samples
A total of 51 patients were consecutively enrolled in this study seen at MD Anderson Cancer Center (MDACC) for a diagnosis and classification of MDS according to the WHO, FrenchAmerican-British (FAB) and International Prognostic Scoring System (IPSS) systems [16] [17] [18] Table 1 and Supplementary Tables 1 and 2 . Buccal swabs and bone marrow aspirates were obtained with informed consent. Mononuclear cells were isolated from bone marrow aspirates by Ficoll centrifugation, and when sufficient cells were available, two-third of these cells were further purified by magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) to obtain the CD34 þ fraction. Cells were lysed in Gentra Puregene buffer (Qiagen, Hilden, Germany). DNA from buccal swabs and the bone marrow cell lysates were prepared with the Gentra Puregene kit (Qiagen) and analyzed by spectrometry (Nanodrop Technologies, Wilmington, DE, USA).
SNP array analysis
Mononuclear bone marrow cell DNA and matched normal DNA from all 51 patients, together with the DNA from CD34 þ bone marrow cells from 24 of these patients, was analyzed with Genechip Mapping 250K StyI arrays according to the manufacturer's protocol (Affymetrix, Santa Clara, CA, USA). The data were analyzed with dChip (version 5 August 2008). 19 Raw data were normalized and modeled (PM/MM difference). Copy number values were computed by the 'batch normalization' and 'scaling copy number mode to 2 copies' algorithms. The raw data were inferred by the 'median smoothing' algorithm and a window of 10 SNPs. To obtain standardized intensities (copy number values) across all probe sets, the log2 ratio was computed as log2 (signal intensity/mean signal intensity of all normal samples for a given SNP probe set). As a quality control, the standard deviation of the raw log2 ratio for each SNP probe set minus the raw log2 ratio for the adjacent SNP probe set was calculated along chromosome 1. Only samples with a standard deviation of 0.6 or smaller were included in the analysis. Reported segments of deletion or amplification (Supplementary  Tables 1-3) were obtained by the Hidden Markov Model algorithm using a step of 0.2 and a standard deviation of 0.4. Only regions with a coverage of at least five consecutive probe sets, an absolute average value of 0.2 and visual confirmation are reported. To identify CNVs, each matched normal sample was analyzed in the same way. LOH was inferred by the Hidden Markov Model. The LOH analysis for each patient was based on the comparison with the matched normal DNA. Only segments with an LOH probability greater than 0.8 were considered as LOH. UPDs were identified as copy-neutral LOH by comparison with the results of the copy number analysis. In addition to the LOH probability criterion, UPD regions had to have at least six LOH calls (all LOH calls minus all conflict calls within that region) to be reported. As a third criterion, regions containing less than 5% informative calls were disregarded. Intervening segments of apparent retention were considered as LOH by comparison to their copy number status or if the number of calls was less than 6 (all retention calls minus all conflict calls within the segment). For the unpaired analysis all normal samples were disregarded. Instead, a reference genotype file containing 60 normal controls from the CEPH subset of the HapMap project 20 was used for the LOH analysis. All other parameters remained unchanged. As no individual comparative calls are generated, the threshold for a region to be considered was set to at least 50 probe sets (SNPs) and at least 2 Mb in size.
Results
High frequency of deletions in MDS patients
We analyzed bone marrow samples from 51 patients with newly diagnosed MDS using high-resolution SNP arrays. Their median age was 66 years (range, 43-83 years) and 32 of 51 (63%) had lower risk disease (low or intermediate-1 IPSS scores); 33 (65%) had normal karyotypes by conventional cytogenetic analysis. The distributions of patients by WHO, FAB and IPSS classifications are given in Table 1 . For each patient, we compared the SNP array profiles of bone marrow mononuclear cell DNA with those of matched buccal swab DNA to detect somatically acquired clonal abnormalities of copy number as well as regions of LOH. As MDS originates in hematopoietic stem cells, we also selected CD34 þ cells from bone marrow aspirates of 24 patients and compared the SNP profiles with those of matched bone marrow mononuclear and buccal cells.
DNA copy number analysis identified chromosomal defects, mainly deletions, in 21 (41%) of the 51 patients (Supplementary Figure 1 , also Supplementary Tables 1 and 2 ). Chromosomal gains were less frequent than deletions and were found only in MDS cases with complex karyotypes (Supplementary Table 2 ). Tables 1 and 2 for patient-by-patient characteristics and results.
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The most frequently deleted region (18% of all cases) was located on chromosome 5q, as is typical of cytogenetic findings in MDS. 5 Heterozygous deletions were identified in eight patients (16%), together with a focal homozygous deletion of about 5 Mb within the 5q-deleted region of patient 27 ( Figure 1 , lanes [22] [23] [24] . By conventional karyotyping, this case had both a del(5q) and a t(5;12)(q33;q12) translocation, accounting for the deletion. Although the homozygously deleted region is located outside the two previously defined critical deleted regions (CDRs) on chromosome 5q, [21] [22] [23] three additional cases had a del(5q) that extended to the telomere, thus including the 5 Mb homozygously deleted region.
Examples of recurrent chromosomal gain were also found in this cohort. Two patients (no. 27 and 49) had small regions of gain on chromosome 8 (Supplementary Figure 3) that commonly encompassed the 8q24.13-21 locus, which harbors the MYC gene. Four others (patients 34, 37, 46 and 51) had 11q23 gains in association with multiple complex cytogenetic abnormalities, similar to the findings of others. 24, 25 Among the 24 patients with available CD34 þ cell DNA, 11 (42%) had detectable chromosomal abnormalities by SNP array analysis. In most of these cases, the same aberrations were more readily detected in the purified CD34 þ cells than in mononuclear bone marrow cells (see, for example, Figure 1 , lanes 11 vs 12, 14 vs 15, 17 vs 18 and 23 vs 24), consistent with the origin of MDS in hematopoietic stem cells. Thus, residual normal cells were present in the whole bone marrow mononuclear fractions of MDS patients. A significant fraction of these residual normal cells appeared to be mature T lymphocytes included in the unfractionated bone marrow mononuclear cells, as deletions of the T-cell receptor-a locus (14q11.2) were detected in the bone marrow mononuclear cells of some cases, but not in either the matched CD34 þ cell DNA or the buccal cell DNA (Supplementary Figure 2) . Buccal scrapings from some patients contained a small fraction of clonal blood leukocytes, resulting in a slightly lower than expected copy number for the region that was hemizygously deleted in the malignant clone (see, for example, patient 46 in Figure 1, White areas indicate no copy number change (log2 ratio ¼ 0), whereas shades of blue and red designate losses and gains, respectively (see scale at bottom). All blue areas on the q-arm correspond to heterozygous deletions, except in patient 27, where a homozygously deleted area (dark blue) was found within the heterozygous region of loss. A profile view of the copy number for this patient is shown on the right. The red line indicates the expected normal copy number, whereas the blue line indicates the log2 ratio of the measured copy number along the chromosome. The positions of the two previously described common deleted regions (CDRs) of chromosome 5q are indicated.
Paired SNP array analysis in MDS S Heinrichs et al large regions of copy number gain were also observed at the proximal boundaries of some of the deletions (patients 37 and 46; Figure 1, (Figure 3 ) at 6q21 (3 Mb), 12p13.2 (1.5 Mb) and 21q22.12 (1.2 Mb). The 21q22.12 region contains the RUNX1 gene, and the deletion breakpoint was located within that locus. Alternatively, a cryptic translocation with an accompanying deletion of a small region could have led to the disruption of the intact RUNX1 locus in this patient. Another patient (no. 49) also showed a disruption of the RUNX1 locus by a very small deletion, which was detected in the context of other abnormalities discernible by standard karyotyping. RUNX1 encodes a critical regulator of hematopoietic differentiation and can be inactivated by mutation or translocation in both MDS and acute myeloid leukemia (AML). 27, 28 Thus, SNP array analysis can pinpoint small regions of deletion that harbor tumor suppressor genes, such as RUNX1, which are often mutated in MDS.
Association of UPD 7q with a deteriorating clinical course
The short follow-up times for this study group precluded a statistical analysis of the association between SNP array findings and the clinical outcome of therapy. Within the normal karyotype subgroup (n ¼ 33), however, we noted that the two patients identified as having UPDs affecting the long arm of chromosome 7 (Figure 4 ) experienced a deteriorating clinical course. One patient (no. 5) was a 56-year-old woman with refractory anemia and an IPSS score of zero who had a UPD at 7q22.1-7qtel at presentation. Over the next 10 months, she developed rapidly increasing bone marrow blast counts and worsening cytopenias and died. The other patient (no. 7) was a 67-year-old man with refractory anemia and a hypercellular bone marrow showing multilineage dysplasia and an IPSS score of zero. At presentation he had a UPD at 7q31.33-7qtel. Over the next 12 months, he developed thrombocytopenia, leukocytosis and pleural effusions, and died. The finding of a chromosome 7 cytogenetic abnormality in MDS confers a higher risk score according to the IPSS criteria. 17 In these two patients with normal bone marrow cell karyotypes, our results suggest that UPD 7q detected by SNP array may identify the same subset of higher risk patients as does a cytogenetic abnormality of chromosome 7 (Figure 4 ).
Requirement for matched normal DNA in SNP array analysis
The human genome contains structural variations consisting of thousands of regions in which segments of DNA have been gained or lost. These so-called CNVs, constitute much of the inherited variation among individuals. [29] [30] [31] A growing number of the most frequently occurring CNVs have been cataloged in databases, 32 and must be considered in the interpretation of SNP array results; however, additional CNVs occur at low frequency in human populations and have not yet been included in existing databases. 
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Published SNP array analyses of bone marrow cells from MDS patients [11] [12] [13] [14] [15] have relied mainly on CNV databases and DNA samples from unrelated individuals, rather than on paired samples of normal DNA for each patient, to substantiate regions of MDS-related copy number aberrations or UPD. This method can yield spurious results, as low allelic frequencies of inherited CNVs and linkage disequilibrium in the inheritance of linked SNPs can often mimic small regions of deletion or gain, as well as acquired UPDs, in an unpaired analysis. Thus, we reanalyzed the SNP array data from our patient cohort with normal bone marrow cell karyotypes (n ¼ 33) to determine the proportion of inherited polymorphisms and CNVs that would be erroneously identified as clonal, somatically acquired genomic abnormalities without the use of individual normal controls. By this approach, we identified 31 nonredundant copy number changes, mainly deletions, in 27 of the patients; their sizes ranged from 0.4 to 1897 kb (minimal coverage 5 consecutive SNPs). Analysis with paired normal DNA samples revealed that only 3 of these lesions were true microdeletions, whereas 28 were CNVs. Even on reconciliation with a CNV database, 32 6 (21%) of the 28 CNVs we identified would have been falsely identified as microdeletions. Figure 5a shows examples of 3 CNVs that each occurred only once in the analysis of the 33 patients with a normal karyotype. Each of these areas of copy number loss is readily apparent in both the DNA from bone marrow and the paired buccal swab from the same patient, clearly indicating that they are all inherited CNVs. By contrast, the region of copy number loss identified in the bone marrow cells of patient 26 is not present in the matched buccal DNA sample, identifying this region as a somatically acquired microdeletion. Thus, matched normal controls are needed to reliably detect true copy number alterations.
Similarly, reanalysis of our LOH results, replacing the matched normal DNA samples with 60 unrelated normal controls (CEPH subset of the HapMap project 20 ) identified 110 regions of potential LOH in the 33 patients with a normal karyotype (regions covered by more than 50 SNPs and greater than 2 Mb in size). With use of matched buccal DNA samples, however, we were able to show that only 4 (3.6%) of these 110 regions represented true UPDs. An example of the detection of a true UPD is shown in Figure 5b , in which a large region of chromosome 7q exhibits LOH based on the SNP calls, with region is actually a stretch of apparent homozygosity (only A or B calls), which is maintained in both the normal and the bone marrow DNA of this patient and does not represent a somatically acquired loss and reduplication event leading to UPD (see Supplementary Figure 4 for an additional example). Thus, failure to include paired normal DNA samples in SNP array analysis of bone marrow cells from MDS patients can lead to vastly overestimated frequencies of UPDs and microdeletions, most of which are not linked to somatic abnormalities that have occurred during the genesis of the MDS clone.
Discussion
This prospective study, the first to apply genome-wide SNP array analysis to paired bone marrow and normal DNA specimens from a large cohort of patients with MDS, identified cryptic chromosomal changes with both clinical and molecular genetic implications. Our findings differ in important aspects from those in retrospective studies based on DNA extracted from archived bone marrow cell samples. [11] [12] [13] [14] [15] Importantly, the overall rate of genomic abnormalities in MDS patients with normal bone marrow karyotypes was much lower in our analysis than in earlier studies. We attribute this discrepancy to the lack of paired normal DNA samples in most previous analyses resulting in the spurious identification of inherited CNVs or regions of apparent homozygosity as somatically acquired genomic alterations within the MDS clone. Indeed, we demonstrate that the majority of apparent abnormalities detected by analysis of bone marrow cell DNA alone reflect inherited genomic diversity rather than clonal somatic abnormalities. Thus, a straightforward comparison with matched normal DNA is required to identify unequivocally the more subtle aberrations arising from acquired clonal genomic changes. Hence, an attempt to correlate UPD or copy number changes with clinical outcome 14, 15 in patients who have been incorrectly classified due to uncontrolled assessment of genomic variation will not yield valid results.
Apart from its role in assessing bone marrow cell clonality in newly diagnosed cases of MDS, SNP array analysis promises to help unravel the molecular pathogenesis of these complex stem cell diseases. Indeed, identification of discrete clonal molecular changes in MDS by high-density SNP array analysis will likely provide the best starting point for the discovery of new genetic mutations and signal transduction pathways involved in MDS, leading to the development of more effective targeted therapies. We would emphasize that the smallest regions of copy number alteration or LOH are often the most informative in implicating individual genes for detailed sequence analysis, but these small regions are also the most difficult to distinguish from nonpathologic human germline variations. Hence, consistent use of paired bone marrow and normal DNA samples would also be expected to accelerate the pace of disease allele discovery in MDS. 
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We also addressed the question of whether CD34 þ cell selection is required to assess the clonal aberrations in MDS. All of the aberrations found in the CD34 þ fraction were also identified in unselected mononuclear cells, indicating that the clonality of the MDS bone marrow is remarkably high. Our results suggest that the cells lacking MDS-associated clonal changes in the bone marrow-derived samples are mainly circulating blood T lymphocytes (see Supplementary Figure 2 ), indicating that depletion of mature T cells might be a useful strategy for removing residual normal cells from the bone marrow aspirate. In any event, SNP array analysis in MDS can be performed with the mononuclear fraction of whole bone Paired SNP array analysis in MDS S Heinrichs et al marrow cells, and is therefore clinically feasible even when, as is often the case, the MDS bone marrow sample contains low numbers of cells. We report the identification of UPDs in 4 of 33 patients with a normal karyotype. Notably, all segmental UPDs discovered in this study were terminal (see Supplementary Figure 5 for summary). This suggests that BIR 26 might be a dominant mechanism by which a cell duplicates a somatically acquired event such as a mutation, a microdeletion or an epigenetically suppressed region and consequently become homozygous for this segmental region. BIR appears to be a common repair mechanism at stalled or broken replication forks, however, only the reduplication of a region that contains a genetic or epigenetic alteration conferring a growth advantage to the cell would allow for its clonal dominance and selection, leading to its detection by LOH analysis. In this regard, our findings of nonrandom segmental UPDs help to clarify models purporting to explain the pathogenetic basis of large deletions that are typically observed in MDS cases. Certain large deletions, such as the del(5q), are thought to arise from haploinsufficiency for one or more genes within the targeted regions. 21, 23 Indeed, haploinsufficiency for the RPS14 gene has recently been linked to the pathogenesis of MDS associated with the 5q syndrome; 7 homozygous inactivation is not observed in such cases because the RPS14 protein is essential for cellular protein synthesis. Consistent with this model of molecular pathogenesis, we did not observe any UPD affecting 5q in MDS cases. Apparently, deletion of one allele of 5q is sufficient for pathogenesis, and loss of the wild-type alleles with reduplication of mutated or microdeleted target genes on 5q, as would occur with a UPD, is strongly selected against, because it is lethal to the MDS stem cell. By contrast, we did observe UPD affecting the same deleted region that is affected in cases with cytogenetically apparent loss of the long arm of chromosome 7. This implies that at least one mutated or epigenetically suppressed gene in this region is likely reduplicated together with loss of the normal allele in cases with 7q UPD, fulfilling Knudsen's hypothesis for the homozygous inactivation of classical tumor suppressor genes. 33 We hypothesize that genes within the region of UPD on chromosome 7 are likely to harbor inactivating point mutations that will eventually be identified by judicious sequencing of the involved genes in specific cases with UPD. By contrast, other regions of UPD that do not correspond to regions of cytogenetic deletion may harbor activating mutations that are duplicated by UPD and thus provide a growth advantage. 34 FLT3 mutations in AML fit the latter category, in that they are frequently identified on both alleles in AML cases with a normal karyotype. Thus, SNP array analysis can provide critical information needed to pinpoint and identify mutated genes and altered signal transduction pathways in MDS.
A major goal of our study was to detect clonal genomic abnormalities in MDS patients that could be used to improve the clinical management of these disorders. Although longer followup times are needed to determine the association of our SNP array findings with treatment outcome, several results appear to have immediate relevance to patient management. The ability to detect clonal genomic aberrations in cases with a normal bone marrow cell karyotype using SNP array analysis can distinguish MDS from other causes of bone marrow cell dysplasia and pancytopenia due to the effects of drugs, environmental toxins or aberrant immune responses, thus aiding in the initial diagnosis. Moreover, our identification of UPDs affecting chromosome 7 in two patients with low-risk IPSS scores who later showed rapidly deteriorating clinical courses is intriguing.
UPD selects for homozygosity of a specific genomic region, and the same region of chromosome 7q affected by UPD is also very often deleted in MDS cases. When identified by cytogenetic analysis, abnormalities of chromosome 7q by themselves signify an increased IPSS score. Thus, it is possible that the 7q UPDs we identified are equivalent to a deletion in this region and may constitute a high-risk feature in MDS. 17 Whether UPDs affecting this and other genomic regions convey important prognostic information is an important question to address in additional prospective studies using SNP array technology to evaluate patients with MDS entering clinical therapeutic trials.
